Publication | Closed Access

A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide

VaccinationHtert Cryptic PeptideCancer ImmunosurveillancePhase Ii TrialMedicineImmunologyTumor ImmunityTherapeutic VaccineAntigen ProcessingImmunologic ResponseImmunotherapeuticsHla TypingImmunotherapyOncologyRadiation OncologyLung Cancer